PMID- 28769566 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200930 IS - 1176-6336 (Print) IS - 1178-203X (Electronic) IS - 1176-6336 (Linking) VI - 13 DP - 2017 TI - Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure. PG - 887-895 LID - 10.2147/TCRM.S137654 [doi] AB - BACKGROUND: Left ventricular ejection fraction (LVEF) is the most widely used parameter to evaluate the cardiac function in patients with heart failure (HF). However, the association between LVEF and contrast-induced nephropathy (CIN) is still controversial. Therefore, the aim of this study is to evaluate the association of LVEF with CIN and long-term mortality following coronary angiography (CAG) or intervention in patients with HF. METHODS: We analyzed 1,647 patients with HF (New York Heart Association [NYHA] or Killip class >1) undergoing CAG or intervention, including 207 (12.57%) patients with reduced LVEF (HFrEF), 238 (14.45%) with mid-range LVEF (HFmrEF) and 1,202 (72.98%) with preserved LVEF (HFpEF). CIN was defined as an absolute increase of >/=0.5 mg/dL or a relative increase of >/=25% from baseline serum creatinine within 48-72 h after contrast medium exposure. Multivariable logistic regression and Cox proportional hazards regression analyses were performed to identify the association between LVEF, CIN and long-term mortality, respectively. RESULTS: Overall, 225 patients (13.7%) developed CIN. Individuals with lower LVEF were more likely to develop CIN (HFrEF, HFmrEF and HFpEF: 18.4%, 21.8% and 11.2%, respectively; P<0.001), but without a significant trend after adjusting for the confounding factors (HFrEF vs HFpEF: odds ratio [OR] =1.01; HFmrEF vs HFpEF: OR =1.31; all P>0.05). However, advanced HF (NYHA class >2 or Killip class >1) was an independent predictor of CIN (adjusted OR =1.54, 95% confidence interval [CI], 1.07-2.22; P=0.019). During the mean follow-up of 2.3 years, reduced LVEF (HFrEF group) was significantly associated with increased mortality (HFrEF vs HFpEF: adjusted hazard ratio =2.88, 95% CI, 1.77-4.69; P<0.001). CONCLUSION: In patients with HF undergoing CAG or intervention, not worsened LVEF but advanced HF was associated with an increased risk of CIN. In addition, reduced LVEF was an independent predictor of long-term mortality following cardiac catheterization. FAU - Wang, Kun AU - Wang K AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Li, Hua-Long AU - Li HL AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Bei, Wei-Jie AU - Bei WJ AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Guo, Xiao-Sheng AU - Guo XS AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Chen, Shi-Qun AU - Chen SQ AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Islam, Sheikh Mohammed Shariful AU - Islam SMS AD - The George Institute for Global Health, University of Sydney, Camperdown, NSW, Australia. FAU - Chen, Ji-Yan AU - Chen JY AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Liu, Yong AU - Liu Y AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. FAU - Tan, Ning AU - Tan N AD - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences. AD - School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20170719 PL - New Zealand TA - Ther Clin Risk Manag JT - Therapeutics and clinical risk management JID - 101253281 PMC - PMC5529088 OTO - NOTNLM OT - cardiac catheterization OT - contrast-induced nephropathy OT - heart failure OT - left ventricular ejection fraction COIS- Disclosure The authors report no conflicts of interest in this work. EDAT- 2017/08/05 06:00 MHDA- 2017/08/05 06:01 PMCR- 2017/07/19 CRDT- 2017/08/04 06:00 PHST- 2017/08/04 06:00 [entrez] PHST- 2017/08/05 06:00 [pubmed] PHST- 2017/08/05 06:01 [medline] PHST- 2017/07/19 00:00 [pmc-release] AID - tcrm-13-887 [pii] AID - 10.2147/TCRM.S137654 [doi] PST - epublish SO - Ther Clin Risk Manag. 2017 Jul 19;13:887-895. doi: 10.2147/TCRM.S137654. eCollection 2017.